Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Christopher Raymond

Investors Slaughter Q32 Bio On A 'Messy' Update In Eczema, Alopecia Treatment

Q32 Bio delivered a "messy" update for its eczema and alopecia treatment, leading the biotech stock to collapse to a record low.

Investors Business Daily

Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake'

Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.

Investors Business Daily

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.

Pfizer stock closed flat Thursday after the company pulled its sickle cell drug, Oxbryta, from the market following patient deaths.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks

There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.

Investors Business Daily

Biogen Stock Surges After Two Notable Products Walloped Sales Expectations

Two of Biogen's newest drugs walloped first-quarter sales expectations on Wednesday, and helped Biogen stock jump.

Investors Business Daily

Vertex Breaks Out To Record High As It Takes On Opioids In Pain Treatment

Vertex solidified its potential for an alternative to opioids in pain treatment, an analyst said Wednesday. VRTX stock broke out.

Investors Business Daily

Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales

Regeneron and Sanofi said Monday their blockbuster drug, Dupixent, significantly improved symptoms COPD symptoms.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Biohaven, Yet Another Rival To Argenx In Autoimmune Drugs, Just Rocketed 33%

Biohaven could rival Argenx and Immunovant after unveiling results Wednesday for an autoimmune diseases drug. BHVN stock rocketed.

Investors Business Daily

Regeneron Hits A New Record High On The Approval That 'Could Not Come Soon Enough'

Shares of REGN stock jumped Monday after the FDA approved Regeneron Pharmaceuticals' high-dose Eylea following a delay this summer.

Investors Business Daily

Biohaven, A Top 2% Stock, Exits 'Stealth Mode' And Hits A Record High

Biohaven is coming "out of stealth mode," an analyst said Thursday as BHVN stock climbed for a fourth consecutive day.

Investors Business Daily

Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter Sales

Incyte stock plummeted Tuesday as seasonality hacked at first-quarter revenue and profit with notable sales misses from Jakafi and Opzelura.

Investors Business Daily

AbbVie's Humira: The Downfall Won't Be As 'Draconian' As Initially Expected

AbbVie stock won at least one upgrade Friday after issuing long-awaited guidance for Humira for the first year it faces new competition.

Investors Business Daily

Top-Notch Medical Stocks Incyte, Haemonetics Beat — And Shares Crumbled

Incyte stock fell Tuesday after topping quarterly expectations, while fellow medical outlet Haemonetics tumbled on its beat.

Investors Business Daily

Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric

Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

Boeing’s chief sustainability officer: ‘We can’t count on hydrogen-powered commercial flights before 2050’

The world's airplane fleet can't just switch overnight to hydrogen to achieve net zero, says Christopher Raymond, Boeing's chief sustainability officer.

Benzinga

7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%

Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital Markets On Biogen

Investors Business Daily

Biohaven Stock Dives As 'Hand-Wringing' Clouds Two Potentially Promising Deals

Biohaven inked a pair of deals Friday to outfit its pipeline with several new drugs, but BHVN stock plummeted on quarterly losses.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

142 stories

SNY

135 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.